Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain.
about
Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory DermatosesCan antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?T cell receptor gene in synovial tissues of rheumatoid arthritis.Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activityExquisite specificity and peptide epitope recognition promiscuity, properties shared by antibodies from sharks to humans.Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.Immunomodulatory action of intravenous immunoglobulin.Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.Autoantibodies to the alpha/beta T-cell receptors in human immunodeficiency virus infection: dysregulation and mimicry.IVIG in APS pregnancy.Clinical uses of intravenous immunoglobulin.The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease.Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.Human monoclonal natural autoantibodies against the T-cell receptor inhibit interleukin-2 production in murine T cells.Development of an immune system.T cell receptor peptides in treatment of autoimmune disease: rationale and potential.Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation.Fine specificity analysis of autoantibodies to T cell receptor CDR1 segments in rheumatoid arthritis.Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis.Injection of T-cell receptor peptide reduces immunosenescence in aged C57BL/6 mice.Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein.Immune modulation of i.v. immunoglobulin in women with reproductive failure.Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases: A Mechanistic Perspective
P2860
Q26765226-D556C652-097F-4557-B14B-5406276EBA92Q33364381-6876A16F-67A0-4269-A646-5767E1201165Q33536193-C7303123-F1C8-4EEF-B3F0-12548ED517A9Q33596381-F25A4553-C218-428D-B583-5430846FE268Q33817905-DCC36717-4679-4FB8-AEE4-23AA65AE8EBAQ34218267-E29439CE-2FAC-42E7-8071-94B6A50C2BB5Q34620111-0901F76D-EA83-412A-92D4-93E032018BF7Q35013334-BAD41267-FC49-47C5-9167-DC3339A613F5Q35140380-121AA49D-94E8-4032-A50B-A3C055E8CCD2Q35715908-A322CE8D-C280-4E45-9957-E718AE130889Q35882020-88771750-E618-448B-9077-BC92D2DA65CCQ35918396-E7231B0F-AF5E-4C75-AED6-EB2F9E666395Q36264883-262170AA-78A4-4A18-B421-2565CFA1E7C4Q36362274-98D33352-D9D2-449F-87C8-5CAD9CD0D559Q36482693-4B5B7920-A843-41A7-AA01-E6DA6C8A0829Q36484438-A9C27337-CD3A-4E21-8A0F-B4412C14D7AAQ37351865-309A9C06-44EB-4037-8317-848A9E65D2F3Q37773248-9B0DAFE4-C1D6-43D3-ADEF-0789492FEBEBQ38203801-C3759500-D452-4EF0-9D5A-B125FD8DD067Q39579621-42A456E2-1320-4190-B990-2CAF55500895Q40734975-A80DCC33-E21C-47E9-8A81-0571FD6B4817Q40756763-B91CFE3C-7719-439D-8D85-079D8B4D2916Q41027832-CB48CAF4-220F-4D4E-8A13-DD41224166F4Q41589724-ABF16806-772B-4F1F-89D3-C4E76B9986D9Q45276421-D1082576-BB08-4DF3-BA21-6C647AC6A7A1Q46071222-C815B6AB-6FB1-474B-B577-856B0AF2DD90Q46793483-EA90454F-B1C7-4E0F-B062-569FE9D008E3Q47865077-C7880F16-6742-43FC-8FF9-8E48028257A6Q47915965-C47221C6-D1D4-4280-9396-C6F44B0FE8DCQ55094703-3D56323F-6F8A-45F6-8178-A3CEAE3AC71DQ58864646-FDAA69B7-16C6-40BD-BD6A-F10556C75E99
P2860
Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@ast
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@en
type
label
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@ast
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@en
prefLabel
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@ast
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@en
P2093
P2860
P356
P1476
Human autoantibodies reactive ...... om T-cell receptor beta chain.
@en
P2093
A B Edmundson
F Dedeoglu
J J Marchalonis
S F Schluter
P2860
P304
P356
10.1073/PNAS.89.8.3325
P407
P577
1992-04-01T00:00:00Z